Submitted:
29 May 2026
Posted:
01 June 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
3.1. Baseline Characteristics
3.2. Salivary Microbial qPCR Signals Across PCOS Phenotypes and Controls
3.3. Post-Hoc Pairwise Comparisons and Exploratory Discriminatory Analyses
3.4. Exploratory Correlation Analysis Among Women with PCOS
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod. 2004, 19(1), 41–47. [Google Scholar] [CrossRef] [PubMed]
- Teede, H.J.; Tay, C.T.; Laven, J.J.E.; Dokras, A.; Moran, L.J.; Piltonen, T.T.; et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum. Reprod. 2023, 38(9), 1655–1679. [Google Scholar] [CrossRef] [PubMed]
- Azziz, R.; Carmina, E.; Chen, Z.; Dunaif, A.; Laven, J.S.E.; Legro, R.S.; et al. Polycystic ovary syndrome. Nat. Rev. Dis. Prim. 2016, 2, 16057. [Google Scholar] [CrossRef]
- Joham, A.E.; Norman, R.J.; Stener-Victorin, E.; Legro, R.S.; Franks, S.; Moran, L.J.; et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022, 10(9), 668–680. [Google Scholar] [CrossRef]
- Stener-Victorin, E.; Teede, H.; Norman, R.J.; Legro, R.; Goodarzi, M.O.; Dokras, A.; et al. Polycystic ovary syndrome. Nat. Rev. Dis. Prim. 2024, 10(1), 27. [Google Scholar] [CrossRef] [PubMed]
- Mumusoglu, S.; Yildiz, B.O. Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Curr. Opin. Endocr. Metab. Res. 2020, 12, 66–71. [Google Scholar] [CrossRef]
- Bozdag, G.; Mumusoglu, S.; Zengin, D.; Karabulut, E.; Yildiz, B.O. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. 2016, 31(12), 2841–2855. [Google Scholar] [CrossRef]
- Daan, N.M.P.; Louwers, Y.V.; Koster, M.P.H.; Eijkemans, M.J.C.; de Rijke, Y.B.; Lentjes, E.G.W.M.; et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil. Steril. 2014, 102(5), 1444–1451.e3. [Google Scholar] [CrossRef]
- Lindheim, L.; Bashir, M.; Münzker, J.; Trummer, C.; Zachhuber, V.; Leber, B.; et al. The salivary microbiome in polycystic ovary syndrome (PCOS) and its association with disease-related parameters: a pilot study. Front Microbiol. 2016, 7, 1270. [Google Scholar] [CrossRef]
- Sola-Leyva, A.; Pérez-Prieto, I.; Molina, N.M.; Vargas, E.; Ruiz-Durán, S.; Leonés-Baños, I.; et al. Microbial composition across body sites in polycystic ovary syndrome: a systematic review and meta-analysis. Reprod. BioMed Online 2023, 47(1), 129–150. [Google Scholar] [CrossRef]
- Lindheim, L.; Bashir, M.; Münzker, J.; Trummer, C.; Zachhuber, V.; Leber, B.; et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS ONE 2017, 12(1), e0168390. [Google Scholar] [CrossRef]
- Torres, P.J.; Siakowska, M.; Banaszewska, B.; Pawelczyk, L.; Duleba, A.J.; Kelley, S.T.; et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J. Clin. Endocrinol. Metab. 2018, 103(4), 1502–1511. [Google Scholar] [CrossRef]
- Guo, Y.; Qi, Y.; Yang, X.; Zhao, L.; Wen, S.; Liu, Y.; et al. Association between polycystic ovary syndrome and gut microbiota. PLoS ONE 2016, 11(4), e0153196. [Google Scholar] [CrossRef] [PubMed]
- Qi, X.; Yun, C.; Sun, L.; Xia, J.; Wu, Q.; Wang, Y.; et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat. Med. 2019, 25(8), 1225–1233. [Google Scholar] [CrossRef]
- Parker, J.; O’Brien, C.; Hawrelak, J. A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome. Obstet. Gynecol. Sci. 2022, 65(1), 14–28. [Google Scholar] [CrossRef]
- Thackray, V.G. Sex, microbes, and polycystic ovary syndrome. Trends Endocrinol. Metab. 2019, 30(1), 54–65. [Google Scholar] [CrossRef] [PubMed]
- Lu, C.; Wang, H.; Yang, J.; Zhang, X.; Chen, Y.; Feng, R.; et al. Changes in vaginal microbiome diversity in women with polycystic ovary syndrome. Front Cell Infect. Microbiol. 2021, 11, 755741. [Google Scholar] [CrossRef]
- He, F.; Li, Y. The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population. J. Ovarian Res. 2021, 14(1), 50. [Google Scholar] [CrossRef] [PubMed]
- Zhou, L.; Ni, Z.; Cheng, W.; Yu, J.; Sun, S.; Zhai, D.; et al. Characteristic gut microbiota and predicted metabolic functions in women with PCOS. Endocr. Connect. 2020, 9(1), 63–73. [Google Scholar] [CrossRef]
- Yu, Z.; Qin, E.; Cheng, S.; Yang, H.; Liu, R.; Xu, T.; et al. Gut microbiome in PCOS associates to serum metabolomics: a cross-sectional study. Sci. Rep. 2022, 12, 22184. [Google Scholar] [CrossRef]
- Guo, J.; Shao, J.; Yang, Y.; Niu, X.; Liao, J.; Zhao, Q.; et al. Gut microbiota in patients with polycystic ovary syndrome: a systematic review. Reprod. Sci. 2022, 29(1), 69–83. [Google Scholar] [CrossRef]
- Min, Q.; Geng, H.; Gao, Q.; Xu, M. The association between gut microbiome and PCOS: evidence from meta-analysis and two-sample Mendelian randomization. Front Microbiol. 2023, 14, 1203902. [Google Scholar] [CrossRef]
- Suturina, L.; Belkova, N.; Igumnov, I.; Lazareva, L.; Danusevich, I.; Nadeiaeva, I.; et al. Polycystic ovary syndrome and gut microbiota: phenotype matters. Life 2023, 13(1), 7. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Chang, Q.; Luo, Y.; Pan, J.; Hu, Y.; Liu, B.; et al. The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones. Front Cell Dev. Biol. 2024, 12, 1384233. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Cheng, J.; Liu, C.; Zhang, X.; Ma, N.; Zhou, Z.; et al. Gut microbiota in women with polycystic ovary syndrome: an individual based analysis of publicly available data. EClinicalMedicine 2024, 77, 102884. [Google Scholar] [CrossRef] [PubMed]
- Sun, J.; Wang, M.; Kan, Z. Causal relationship between gut microbiota and polycystic ovary syndrome: a literature review and Mendelian randomization study. Front Endocrinol. 2024, 15, 1280983. [Google Scholar] [CrossRef]
- Talebi, S.; Zeraattalab-Motlagh, S.; Jalilpiran, Y.; Payandeh, N.; Ansari, S.; Mohammadi, H.; et al. The effects of pro-, pre-, and synbiotics supplementation on polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials. Front Nutr. 2023, 10, 1178842. [Google Scholar] [CrossRef]
- Mehta, P.; Saha, D.; Das, A.; Das, B.K. Gut microbiota in diabetic-linked polycystic ovarian syndrome: mechanisms and therapeutic insights. Tissue Cell. 2025, 95, 102870. [Google Scholar] [CrossRef]
- Senthilkumar, H.; Arumugam, M. Gut microbiota: a hidden player in polycystic ovary syndrome. J. Transl. Med. 2025, 23(1), 443. [Google Scholar] [CrossRef]
- Li, J.; Qiao, J.; Li, Y.; Qin, G.; Xu, Y.; Lao, K.; et al. Metabolic disorders in polycystic ovary syndrome: from gut microbiota biodiversity to clinical intervention. Front Endocrinol. 2025, 16, 1526468. [Google Scholar] [CrossRef]
- Zhao, M.; Chen, D.; Hu, X.; Xie, C.; Xu, L.; Zhou, F. Gut-ovary axis in polycystic ovary syndrome: mechanistic insights and gut microbiota-targeted therapeutic strategies. Front Endocrinol. 2025, 16, 1684492. [Google Scholar] [CrossRef]
- Anderson, R.C.; Cookson, A.L.; McNabb, W.C.; Park, Z.; McCann, M.J.; Kelly, W.J.; et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010, 10, 316. [Google Scholar] [CrossRef] [PubMed]
- Mujagic, Z.; de Vos, P.; Boekschoten, M.V.; Govers, C.; Pieters, H.J.H.M.; de Wit, N.J.W.; et al. The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription: a randomized double-blind placebo controlled trial. Sci. Rep. 2017, 7, 40128. [Google Scholar] [CrossRef] [PubMed]
- Kovatcheva-Datchary, P.; Nilsson, A.; Akrami, R.; Lee, Y.S.; De Vadder, F.; Arora, T.; et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab. 2015, 22(6), 971–982. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, H.K.; Gudmundsdottir, V.; Nielsen, H.B.; Hyötyläinen, T.; Nielsen, T.; Jensen, B.A.H.; et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016, 535(7612), 376–381. [Google Scholar] [CrossRef]
- De Filippis, F.; Pasolli, E.; Tett, A.; Tarallo, S.; Naccarati, A.; De Angelis, M.; et al. Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets. Cell Host Microbe 2019, 25(3), 444–453.e3. [Google Scholar] [CrossRef]
- Precup, G.; Vodnar, D.C. Gut Prevotella as a possible biomarker of diet and its eubiotic versus dysbiotic roles: a comprehensive literature review. Br. J. Nutr. 2019, 122(2), 131–140. [Google Scholar] [CrossRef]
- Shabbir, S.; Khurram, E.; Moorthi, V.S.; Mistry, V.; Butler, A.E.; Abu-Farha, M. The interplay between androgens and the immune response in polycystic ovary syndrome. J. Transl. Med. 2023, 21(1), 259. [Google Scholar] [CrossRef]
- Schüler-Toprak, S.; Ortmann, O.; Buechler, C.; Treeck, O. The complex roles of adipokines in polycystic ovary syndrome and endometriosis. Biomedicines 2022, 10(10), 2503. [Google Scholar] [CrossRef]
- Liu, J.; Liu, Y.; Li, X. Effects of intestinal flora on polycystic ovary syndrome. Front Endocrinol. 2023, 14, 1151723. [Google Scholar] [CrossRef]
- Lundmark, A.; Hu, Y.O.O.; Huss, M.; Johannsen, G.; Andersson, A.F.; Yucel-Lindberg, T. Identification of salivary microbiota and its association with host inflammatory mediators in periodontitis. Front Cell Infect. Microbiol. 2019, 9, 216. [Google Scholar] [CrossRef] [PubMed]
- Ferriman, D.; Gallwey, J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 1961, 21(11), 1440–1447. [Google Scholar] [CrossRef]
- Greene, J.C.; Vermillion, J.R. The simplified oral hygiene index. J. Am. Dent. Assoc. 1964, 68, 7–13. [Google Scholar] [CrossRef] [PubMed]
- Shapiro, S.S.; Wilk, M.B. An analysis of variance test for normality (complete samples). Biometrika 1965, 52(3-4), 591–611. [Google Scholar] [CrossRef]
- Kruskal, W.H.; Wallis, W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 1952, 47(260), 583–621. [Google Scholar] [CrossRef]
- Mann, H.B.; Whitney, D.R. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 1947, 18(1), 50–60. [Google Scholar] [CrossRef]
- Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R Stat. Soc. Ser. B Stat. Methodol. 1995, 57(1), 289–300. [Google Scholar] [CrossRef]
- Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55(4), 611–622. [Google Scholar] [CrossRef]
| Characteristic | Phenotype A (n=23) |
Phenotype B (n=19) |
Phenotype C (n=22) |
Phenotype D (n=23) |
Control (n=23) |
p-value |
|---|---|---|---|---|---|---|
| Sample size, n | 23 | 19 | 22 | 23 | 23 | - |
| Age, years | 28 (19-40) | 29 (22-38) | 28 (18-42) | 30 (21-40) | 29 (20-38) | 0.811 |
| Ferriman-Gallwey score | 8.0 (5.0-18.0) | 7.0 (5.0-12.0) | 6.5 (5.0-14.0) | 3.0 (0.0-4.0) | 0.0 (0.0-2.0) | <0.001 |
| Menstrual irregularity or ovulatory dysfunction, n (%) | 23 (100.0) | 19 (100.0) | 0 (0.0) | 23 (100.0) | 0 (0.0) | <0.001 |
| Polycystic ovarian morphology on TVS, n (%) | 23 (100.0) | 0 (0.0) | 22 (100.0) | 23 (100.0) | 0 (0.0) | <0.001 |
| Microbiota | Phenotype A (n = 23) |
Phenotype B (n = 19) |
Phenotype C (n = 22) |
Phenotype D (n = 23) |
Control (n = 23) |
p-value |
|---|---|---|---|---|---|---|
| Lactobacillus | 32.50 (12.34–36.82) |
34.46 (27.84–37.22) |
35.42 (11.76–36.98) |
34.46 (26.64–37.00) |
35.59 (27.74–36.85) |
0.249 |
| Prevotella | 22.32 (19.11–35.68) |
21.42 (18.70–35.95) |
24.28 (18.21–32.20) |
31.00 (19.44–37.03) |
28.43 (20.54–36.77) |
<0.001 |
| Bifidobacterium | 36.77 (27.94–37.25) |
36.44 (11.76–37.16) |
36.64 (35.35–37.09) |
35.71 (31.96–37.13) |
35.71 (5.92–37.01) |
<0.001 |
| Microbiota | Comparison | Raw p-value | Bonferroni-adjusted p-value | Interpretation |
|---|---|---|---|---|
| Prevotella | Phenotype A vs Phenotype D | <0.001 | 0.010 | Significant |
| Prevotella | Phenotype A vs Control | <0.001 | 0.010 | Significant |
| Prevotella | Phenotype B vs Phenotype D | <0.001 | 0.010 | Significant |
| Prevotella | Phenotype B vs Control | <0.001 | 0.010 | Significant |
| Prevotella | Phenotype C vs Phenotype D | 0.002 | 0.020 | Significant |
| Prevotella | Phenotype C vs Control | 0.004 | 0.040 | Significant |
| Bifidobacterium | Phenotype A vs Control | <0.001 | 0.010 | Significant |
| Bifidobacterium | Phenotype C vs Control | <0.001 | 0.010 | Significant |
| Clinical variable | Microbiota | n | Spearman rho | Raw p-value | FDR-adjusted p-value | Interpretation |
|---|---|---|---|---|---|---|
| Ferriman–Gallwey score | Lactobacillus | 87 | 0.040 | 0.712 | 0.937 | Not significant |
| Ferriman–Gallwey score | Prevotella | 87 | 0.423 | <0.001 | <0.001 | Significant |
| Ferriman–Gallwey score | Bifidobacterium | 87 | -0.283 | 0.008 | 0.023 | Significant |
| Menstrual irregularity/ovulatory dysfunction | Lactobacillus | 87 | 0.125 | 0.247 | 0.557 | Not significant |
| Menstrual irregularity/ovulatory dysfunction | Prevotella | 87 | -0.015 | 0.892 | 0.937 | Not significant |
| Menstrual irregularity/ovulatory dysfunction | Bifidobacterium | 87 | 0.103 | 0.342 | 0.615 | Not significant |
| PCOM on TVS | Lactobacillus | 87 | 0.009 | 0.937 | 0.937 | Not significant |
| PCOM on TVS | Prevotella | 87 | -0.302 | 0.005 | 0.020 | Significant |
| PCOM on TVS | Bifidobacterium | 87 | 0.019 | 0.860 | 0.937 | Not significant |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).